

1. 5,935,821, Aug. 10, 1999, Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma; Malaya Chatterjee, et al., 435/69.6, 69.7, 327, 330; 536/23.4, 23.53 [IMAGE AVAILABLE]

2. 5,290,551, Mar. 1, 1994, Treatment of melanoma with a vaccine comprising irradiated autologous melanoma tumor cells conjugated to a hapten; David Berd, 424/193.1, 85.2, 277.1 [IMAGE AVAILABLE]

=> s 12(3a)14(3a)11

L9                315 L2(3A)L4(3A)L1

=> d history

(FILE 'USPAT' ENTERED AT 08:20:17 ON 19 AUG 1999)

L1	23901 S TUMOR OR TUMOUR
L2	380737 S VACCIN? OR ADMINIST? OR INJECT?
L3	25637 S HAPTEN OR ANTIGEN OR EPITOPE
L4	544967 S OWN OR SELF OR PATIENT?
L5	1028 S L1(10A)L4(10A)L2
L6	464 S L1(3A)L4(10A)L2
L7	262 S L1(3A)L4(3A)L2
L8	2 S L2(A)L4(3A)L1
L9	315 S L2(3A)L4(3A)L1

04/304859

STN  
8/19

L4 ANSWER 1 OF 44 USPATFULL

ACCESSION NUMBER: 1998:147552 USPATFULL  
TITLE: Alternative open reading frame DNA of a normal gene  
and  
a novel human cancer antigen encoded therein  
INVENTOR(S): Wang, Rong-Fu, Bethesda, MD, United States  
Rosenberg, Steven A., Potomac, MD, United States  
PATENT ASSIGNEE(S): The United States of America as represented by the  
Secretary of the Department of Health and Human  
Services, Washington, DC, United States (U.S.  
government)

	NUMBER	DATE
PATENT INFORMATION:	US 5840839	19981124
APPLICATION INFO.:	US 1996-599602	19960209 (8)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	LeGuyader, John L.	
ASSISTANT EXAMINER:	Schwartzman, Robert	
LEGAL REPRESENTATIVE:	Morgan & Finnegan, L.L.P.	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	14 Drawing Figure(s); 8 Drawing Page(s)	
LINE COUNT:	1905	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD In another method of **treatment, autologous** cytotoxic  
lymphocytes or **tumor** infiltrating lymphocytes may be obtained  
from a patient with cancer. The lymphocytes are grown in culture and  
cancer antigen specific. . .

L4 ANSWER 2 OF 44 USPATFULL

ACCESSION NUMBER: 1998:135159 USPATFULL  
TITLE: Identification of TRP-2 as a human tumor antigen  
recognized by cytotoxic T lymphocytes  
INVENTOR(S): Wang, Rong-Fu, Bethesda, MD, United States  
Rosenberg, Steven A., Potomac, MD, United States  
PATENT ASSIGNEE(S): The United States of America as represented by the  
Department of Health and Human Services, Washington,  
DC, United States (U.S. government)

	NUMBER	DATE
PATENT INFORMATION:	US 5831016	19981103
APPLICATION INFO.:	US 1996-725736	19961004 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1996-599602, filed on 9 Feb 1996	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Elliott, George C.	
ASSISTANT EXAMINER:	Schwartzman, Robert	
LEGAL REPRESENTATIVE:	Morgan & Finnegan, L.L.P.	
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 5 Drawing Page(s)	
LINE COUNT:	1628	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DRWD In another method of **treatment, autologous** cytotoxic  
lymphocytes or **tumor** infiltrating lymphocytes may be obtained  
from a patient with cancer. The lymphocytes are grown in culture and  
cancer antigen specific. . .

L4 ANSWER 3 OF 44 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.  
 ACCESSION NUMBER: 1998193951 EMBASE  
 TITLE: Alteration of signal-transducing TCRzeta molecules after adoptive immunotherapy.  
 AUTHOR: Kono K.; Ichihara F.; Iizuka H.; Sekikawa T.; Matsumoto Y.  
 CORPORATE SOURCE: Dr. K. Kono, First Department of Surgery, Yamanashi Medical University, 1110 Shimogato, Tamaho-machi, Nakakoma-gun, Yamanashi 409-3898, Japan  
 SOURCE: Biotherapy, (1998) 12/5 (675-676).  
 Refs: 2  
 ISSN: 0914-2223 CODEN: BITPE  
 COUNTRY: Japan  
 DOCUMENT TYPE: Journal; Conference Article  
 FILE SEGMENT: 016 Cancer  
 026 Immunology, Serology and Transplantation  
 037 Drug Literature Index  
 LANGUAGE: Japanese  
 SUMMARY LANGUAGE: English; Japanese  
 AB . . . after adoptive immunotherapy (AIT) using tumor-associated T lymphocytes (TAL). Autologous TAL were cultured in low-dose IL-2 with repeated stimulation of MMC-treated autologous tumor cells and then adoptively transferred to patients intravenously or intraperitoneally. TCRzeta expression was restored in 3 of 13 treated patients, . . .

L4 ANSWER 4 OF 44 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.  
 ACCESSION NUMBER: 1998099003 EMBASE  
 TITLE: The limited effect of adoptive immunotherapy in patients with gastroenterological tumor.  
 AUTHOR: Kono K.; Ichihara F.; Iizuka H.; Sekikawa T.; Matsumoto Y.  
 CORPORATE SOURCE: Dr. K. Kono, First Department of Surgery, Yamanashi Medical University, 1110 Shimokato, Tamaho-cho, Nakagoma-gun, Yamanashi 409-38, Japan  
 SOURCE: Biotherapy, (1998) 12/1 (65-67).  
 Refs: 1  
 ISSN: 0914-2223 CODEN: BITPE  
 COUNTRY: Japan  
 DOCUMENT TYPE: Journal; Conference Article  
 FILE SEGMENT: 005 General Pathology and Pathological Anatomy  
 016 Cancer  
 026 Immunology, Serology and Transplantation  
 LANGUAGE: Japanese  
 SUMMARY LANGUAGE: English; Japanese  
 AB . . . cancer-specific CTLs from tumor infiltrating lymphocyte (TIL), regional lymph node lymphocyte (RLNL) or tumor associated lymphocyte (TAL) with repeated MMC treated autologous tumor stimulation in the presence of rIL-2 (25 IU/ml), and performed the adoptive transfer to the patients with these CTLs. There. . .

L4 ANSWER 5 OF 44 BIOSIS COPYRIGHT 1999 BIOSIS DUPLICATE 1  
 ACCESSION NUMBER: 1997:305851 BIOSIS  
 DOCUMENT NUMBER: PREV199799613654  
 TITLE: Differences in the recognition of tumor-specific CD8+ T cells derived from solid tumor, metastatic lymph nodes and ascites in patients with gastric cancer.  
 AUTHOR(S): Kono, Koji (1); Ichihara, Fumiko; Iizuka, Hidehiko; Sekikawa, Takayoshi; Matsumoto, Yoshirou  
 CORPORATE SOURCE: (1) First Dep. Surg., Yamanashi Med. Univ., 1110 Tamaho, Yamanashi 409-38 Japan  
 SOURCE: International Journal of Cancer, (1997) Vol. 71, No. 6, pp. 978-981.

DOCUMENT TYPE: Article  
LANGUAGE: English

AB. . . gastric cancer-specific CD8+ T-cell (T-CD8 +) lines derived from different lymphocyte sources in the same patients by repeated stimulation with mitomycin-C-treated autologous tumor cells with low-dose interleukin-2, and we compared recognition patterns among the T-CD8 + derived from solid tumor, lymph node metastasis. . .

L4 ANSWER 6 OF 44 USPATFULL

ACCESSION NUMBER: 93:74205 USPATFULL

TITLE: Cloning of the 38kd Mycoplasma hyorhinis regression-associated antigen

INVENTOR(S): Fareed, George C., Los Angeles, CA, United States  
Sen, Arup, Van Nuys, CA, United States  
Ghosh-Dastidar, Pradip, Los Angeles, CA, United States  
Jar-How, Lee, Los Angeles, CA, United States

PATENT ASSIGNEE(S): International Genetic Engineering, Inc., Santa Monica, CA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5242823	19930907
APPLICATION INFO.:	US 1992-956546	19921002 (7)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1990-474730, filed on 16 Mar 1990, now abandoned which is a continuation-in-part of Ser. No. US 1987-131815, filed on 11 Dec 1987, now abandoned And a continuation-in-part of Ser. No. US 1987-97910, filed on 16 Sep 1987, now abandoned which is a continuation-in-part of Ser. No. US 1988-138923, filed on 4 Jan 1988, now abandoned which is a continuation-in-part of Ser. No. US 1986-837494, filed on 7 Mar 1986, now patented, Pat. No. US 4748112	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Nucker, Christine M.	
ASSISTANT EXAMINER:	Tuscan, Michael	
LEGAL REPRESENTATIVE:	Marshall, O'Toole, Gerstein, Murray & Borun	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 22 Drawing Page(s)	
LINE COUNT:	1685	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
SUMM	. . . 51, 415-417 (1985); and Wallack et al., Surgery, 96, 791-800 (1984). Active specific immunotherapy may also be attempted by systematically <b>injecting autologous</b> (autochthonous) tumor cells (i.e., cells derived from the tumor mass of the same patient) intradermally or subcutaneously. Laucius et al., Cancer, 40, .	

L4 ANSWER 7 OF 44 BIOSIS COPYRIGHT 1999 BIOSIS DUPLICATE 2

ACCESSION NUMBER: 1993:28698 BIOSIS

DOCUMENT NUMBER: PREV199395016898

TITLE: In vitro proliferation and the cytotoxic specificity of a cryopreserved cytotoxic T cell clone reacting against human autologous tumor cells.

AUTHOR(S): Wada, Yoshimasa; Ikeda, Hideyuki; Ueda, Daisuke; Ohta, Masahiko; Takahashi, Shuji; Hirata, Koichi; Sato, Noriyuki (1); Kikuchi, Kokichi

CORPORATE SOURCE: (1) Dep. Pathol., Sapporo Med. Coll., 060 Sapporo Japan  
\*SOURCE: Journal of Immunological Methods, (1992) Vol. 154, No. 2, pp. 235-243.

ISSN: 0022-1759.

DOCUMENT TYPE: Article

LANGUAGE: English  
AB. . . tumor cells in addition to a high concentration (350 U/ml) of rIL-2. Furthermore, these cells were proliferated more efficiently when MMC-treated autologous tumor cells were used in vitro as a feeder and an antigenic stimulant. However, such a high dose IL-2 cultivation resulted. . .

L4 ANSWER 8 OF 44 BIOSIS COPYRIGHT 1999 BIOSIS DUPLICATE 3  
ACCESSION NUMBER: 1993:97311 BIOSIS  
DOCUMENT NUMBER: PREV199395052507  
TITLE: Electron microscopic observation of killer cells induced by mixed culture of lymphocytes with autologous cancer cells and further culture with recombinant interleukin-2.  
AUTHOR(S): Murakami, Hiroki (1); Matsuoka, Hiroaki; Fukiage, Tadairo; Samejima, Yasuhiro; Eura, Masao; Ikawa, Tsutomu; Ishikawa, Takeru; Kanda, Takashi  
CORPORATE SOURCE: (1) Dep. Otolaryngol., Kumamoto Univ. Med. Sch., 1-1-1 Honjo, Kumamoto 860 Japan  
SOURCE: Auris Nasus Larynx, (1992) Vol. 19, No. 3, pp. 175-188. ISSN: 0385-8146.  
DOCUMENT TYPE: Article  
LANGUAGE: English

AB Peripheral blood lymphocytes obtained from 2 patients with hypopharyngeal cancer were cultured with mitomycin C treated autologous tumor cells (autologous MLTC) for 10 days and further cultured with recombinant interleukin 2 (rIL-2). In one case 10-day MLTC induced.

L4 ANSWER 9 OF 44 BIOSIS COPYRIGHT 1999 BIOSIS DUPLICATE 4  
ACCESSION NUMBER: 1991:6907 BIOSIS  
DOCUMENT NUMBER: BA91:6907  
TITLE: INDUCTION OF KILLER CELLS FROM LYMPHOCYTES IN PLEURAL EFFUSION OF ADVANCED LUNG CANCER PATIENTS.  
AUTHOR(S): INOUE Y; SHIJUBO N; UEDE T  
CORPORATE SOURCE: DEP. INTERNAL MED., SECT. 3, SAPPORO MED. COLL., S-1, W-16, CHUO-KU, SAPPORO 060, JPN.  
SOURCE: JPN J CANCER RES, (1990) 81 (10), 1012-1020. CODEN: JJCREP. ISSN: 0910-5050.  
FILE SEGMENT: BA; OLD  
LANGUAGE: English

AB. . . cells was increased at 2 weeks, but it was remarkably reduced at 4 weeks. When PLEL were stimulated by mitomycin C-treated autologous tumor cells during culture, autologous tumor killing activity of PLEL was significantly enhanced even after 4 weeks of cultivation. Cold target. . .

L4 ANSWER 10 OF 44 BIOSIS COPYRIGHT 1999 BIOSIS DUPLICATE 5  
ACCESSION NUMBER: 1991:58023 BIOSIS  
DOCUMENT NUMBER: BR40:23378  
TITLE: IMMUNOLOGICAL ASPECTS OF MAMMARY TUMORS IN DOGS AND CATS A SURVEY INCLUDING OWN STUDIES AND PERTINENT LITERATURE.  
AUTHOR(S): RUTTEN V P M G; MISDORP W; GAUTHIER A; ESTRADA M; MIALOT J P; PARODI A L; RUTTEMAN G R; WEYER K  
CORPORATE SOURCE: DEP. INFECT. DIS. IMMUNOL., SECT. IMMUNOL., FAC. VET. MED., UNIV. UTRECHT, P.O. BOX 80.165, 3508 TD UTRECHT, NETH.  
SOURCE: Vet. Immunol. Immunopathol., (1990) 26 (3), 211-226. CODEN: VIIMDS. ISSN: 0165-2427.  
FILE SEGMENT: BR; OLD  
LANGUAGE: English  
IT Miscellaneous Descriptors  
REVIEW BCG CORYNEBACTERIUM PARVUM VACCINE MITOMYCIN TREATED

L4 ANSWER 11 OF 44 MEDLINE DUPLICATE 6  
 ACCESSION NUMBER: 89272025 MEDLINE  
 DOCUMENT NUMBER: 89272025  
 TITLE: Basic and clinical study of adoptive immunotherapy using  
 cytotoxic T lymphocyte (CTL) against cancers.  
 AUTHOR: Kitsukawa K  
 CORPORATE SOURCE: First Dept. of Internal Medicine, School of Medicine,  
 University of the Ryukyus.  
 SOURCE: GAN TO KAGAKU RYOHO [JAPANESE JOURNAL OF CANCER AND  
 CHEMOTHERAPY], (1989 Apr) 16 (4 Pt 2-2) 1448-54.  
 Journal code: 6T8. ISSN: 0385-0684.  
 PUB. COUNTRY: Japan  
 Journal; Article; (JOURNAL ARTICLE)  
 LANGUAGE: Japanese  
 FILE SEGMENT: Priority Journals; Cancer Journals  
 ENTRY MONTH: 198909  
 AB . . . Her breast cancer was histologically scirrhus type  
 adenocarcinoma which was resistant to antineoplastics. Patient's PBL were  
 cocultured with mitomycin C **treated-autologous**  
**tumor**, and they were proliferated with interleukin 2 or T-cell  
 growth factor (TCGF). Then, these CTL were injected to this patient. .

L4 ANSWER 12 OF 44 BIOSIS COPYRIGHT 1999 BIOSIS DUPLICATE 7  
 ACCESSION NUMBER: 1989:138475 BIOSIS  
 DOCUMENT NUMBER: BA87:73128  
 TITLE: CONTROLLED CLINICAL TRIAL OF ADJUVANT IMMUNOTHERAPY WITH  
 BCG AND NEURAMINIDASE-**TREATED AUTOLOGOUS**  
**TUMOR** CELLS IN LARGE BOWEL CANCER.  
 AUTHOR(S): GRAY B N; WALKER C; ANDREWARTHA L; FREEMAN S; BENNETT R C  
 CORPORATE SOURCE: UNIV. DEP. SURG., ROYAL PERTH HOSP., WELLINGTON ST.,  
 PERTH,  
 WESTERN AUSTRALIA 6000, AUST.  
 SOURCE: J SURG ONCOL, (1989) 40 (1), 34-37.  
 CODEN: JSONAU. ISSN: 0022-4790.  
 FILE SEGMENT: BA; OLD  
 LANGUAGE: English  
 TI CONTROLLED CLINICAL TRIAL OF ADJUVANT IMMUNOTHERAPY WITH BCG AND  
 NEURAMINIDASE-**TREATED AUTOLOGOUS TUMOR** CELLS  
 IN LARGE BOWEL CANCER.

✓ L4 ANSWER 13 OF 44 BIOSIS COPYRIGHT 1999 BIOSIS DUPLICATE 8  
 ACCESSION NUMBER: 1989:52909 BIOSIS  
 DOCUMENT NUMBER: BA87:28909  
 TITLE: MELBOURNE AUSTRALIA TRIAL OF ADJUVANT IMMUNOTHERAPY IN  
 OPERABLE LARGE BOWEL CANCER.  
 AUTHOR(S): GRAY B N; WALKER C; ANDREWARTHA L; FREEMAN S; BENNETT R C  
 CORPORATE SOURCE: UNIV. DEP. SURG., ROYAL PERTH HOSP., WELLINGTON ST.,  
 PERTH,  
 WA 6000, AUST.  
 SOURCE: AUST N Z J SURG, (1988) 58 (1), 43-46.  
 CODEN: ANZJA7. ISSN: 0004-8682.  
 FILE SEGMENT: BA; OLD  
 LANGUAGE: English  
 AB. . . Stage B or C large bowel cancer. The immunotherapy consisted of a 2  
 year programme of vaccinations with BCG and neuraminidase-**treated**  
**autologous tumour** cells. Three hundred and one patients  
 entered the trial. At 5 years of follow-up there is no evidence that  
 this.

L4 ANSWER 14 OF 44 BIOSIS COPYRIGHT 1999 BIOSIS DUPLICATE 9  
 ACCESSION NUMBER: 1987:169753 BIOSIS

DOCUMENT NUMBER: B:88194  
TITLE: TUMOR THERAPY OF NEOPLASTIC DISEASE WITH TUMOR CELLS AND  
NEURAMINIDASE FURTHER EXPERIMENTAL STUDIES ON CHESSBOARD  
VACCINATION IN CANINE MAMMARY TUMORS.  
AUTHOR(S): SEDLACEK H H; HAGMAYER G; SEILER F R  
CORPORATE SOURCE: RES. LAB. OF BEHRINGWERKE AG, D-3550 MARBURG, FRG.  
SOURCE: CANCER IMMUNOL IMMUNOTHER, (1986 (RECD 1987)) 23 (3),  
192-199.  
CODEN: CIIMDN. ISSN: 0340-7004.

FILE SEGMENT: BA; OLD  
LANGUAGE: English

AB. . . was investigated. The i. d. injections were performed in a  
chessboard-like manner: different numbers (105, 106, 107, and 108) of  
mitomycin-**treated autologous tumor** cells  
(M-TC) were each mixed with different amounts (10, 50, and 100 mU) of

VCN. These different mixtures were injected. . .

L4 ANSWER 15 OF 44 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.DUPLICATE 10

ACCESSION NUMBER: 85164706 EMBASE

DOCUMENT NUMBER: 1985164706

TITLE: Treatment of patients with pancreatic endocrine tumours  
using a new long-acting somatostatin analogue symptomatic  
and peptide responses.

AUTHOR: Wood S.M.; Kraenzlin M.E.; Adrian T.E.; Bloom S.R.

CORPORATE SOURCE: Department of Medicine, Royal Postgraduate Medical School,  
Hammersmith Hospital, London W12 0HS, United Kingdom

SOURCE: Gut, (1985) 26/5 (438-444).

CODEN: GUTTAK

COUNTRY: United Kingdom

DOCUMENT TYPE: Journal

FILE SEGMENT: 037 Drug Literature Index  
048 Gastroenterology  
030 Pharmacology  
003 Endocrinology  
016 Cancer  
006 Internal Medicine

LANGUAGE: English

AB . . . for seven months with this analogue which has controlled his  
previously life threatening diarrhoea caused by a malignant VIP secreting  
**tumour**. He gives his **own injection** twice  
daily, and has returned to a full and active life. This is a promising  
agent both for acute treatment. . .

✓ L4 ANSWER 16 OF 44 BIOSIS COPYRIGHT 1999 BIOSIS DUPLICATE 11

ACCESSION NUMBER: 1985:234890 BIOSIS

DOCUMENT NUMBER: BA79:14886

TITLE: COMBINATION CHEMOIMMUNOTHERAPY FOR ADVANCED GASTRIC  
CARCINOMA.

AUTHOR(S): AKIYOSHI T; KAWAGUCHI M; ARINAGA S; MIYAZAKI S; KOBAYASHI F;  
WADA T; TSUJI H

CORPORATE SOURCE: DEP. OF SURGERY, MED. INST. OF BIOREGULATION, KYUSHU  
UNIV.,

4546 TSURUMIBARU, BEPPU 874, JAPAN.

SOURCE: JPN J SURG, (1984) 14 (3), 185-190.

CODEN: JJSGAY. ISSN: 0047-1909.

FILE SEGMENT: BA; OLD

LANGUAGE: English

AB. . . advanced gastric carcinoma were treated with a combination  
chemo-immunotherapy regimen that consisted of active immunotherapy with  
Vibrio cholerae neuraminidase (VCN) **treated autologous**  
**tumor** cells admixed with BCG and drugs including cyclophosphamide,  
mitomycin C (MMC) and 5-fluorouracil, followed by long term tegafur (FT)  
and. . .

L4 ANSWER 17 OF 44 BIOSIS COPYRIGHT 1999 BIOSIS DUPLICATE 12

1 340730 BIOSIS  
ACCESSION NUMBER: BA76:77210  
DOCUMENT NUMBER:  
TITLE: A TRIAL OF ADJUVANT COMBINATION CHEMO IMMUNO THERAPY FOR STAGE III CARCINOMA OF STOMACH.  
AUTHOR(S): AKIYOSHI T; KAWAGUCHI M; ARINAGA S; MIYAZAKI S; KOBAYASHI F; WADA T; TSUJI H  
CORPORATE SOURCE: DEP. OF SURGERY, MED. INSTITUTE OF BIOREGULATION, KYUSHU UNIV., BEPPU, 874 JAPAN.  
SOURCE: J SURG ONCOL, (1984) 26 (2), 86-90.  
CODEN: JSONAU. ISSN: 0022-4790.  
FILE SEGMENT: BA; OLD  
LANGUAGE: English

AB. . . with stage III carcinoma of stomach, following curative resection. The treatment regimen consisted of active immunotherapy with *Vibrio cholerae* neuraminidase (VCN)-**treated autologous tumor** cells admixed with BCG and chemotherapy with drugs such as cyclophosphamide (CY), mitomycin C (MMC) and 5-fluorouracil (FU), which proved.

IT Miscellaneous Descriptors  
HUMAN VIBRIO-CHOLERAEE NEURAMINIDASE **TREATED AUTOLOGOUS TUMOR** CELLS BCG IMMUNOLOGIC-DRUG CYCLOPHOSPHAMIDE MITOMYCIN C 5 FLUORO URACIL TEGAFUR ANTINEOPLASTIC-DRUG SURGERY PROGNOSIS

L4 ANSWER 18 OF 44 SCISEARCH COPYRIGHT 1999 ISI (R)  
ACCESSION NUMBER: 83:598555 SCISEARCH  
THE GENUINE ARTICLE: RR228  
TITLE: IMMUNOTHERAPEUTIC APPROACH OF METASTATIC KIDNEY CANCER USING IMMUNE-RNA (I-RNA) FROM GUINEA-PIGS IMMUNIZED WITH FORMALIN **TREATED AUTOLOGOUS TUMOR-CELLS** (TC)

AUTHOR: CORRADO F (Reprint); PIZZA G; MARTINELLI A  
CORPORATE SOURCE: OSPED M MALPIGHI, DIV UROL 1, I-40139 BOLOGNA, ITALY  
COUNTRY OF AUTHOR: ITALY  
SOURCE: PROSTATE, (1983) Vol. 4, No. 6, pp. 660.  
DOCUMENT TYPE: Conference; Journal  
FILE SEGMENT: LIFE  
LANGUAGE: ENGLISH  
REFERENCE COUNT: No References

TI IMMUNOTHERAPEUTIC APPROACH OF METASTATIC KIDNEY CANCER USING IMMUNE-RNA (I-RNA) FROM GUINEA-PIGS IMMUNIZED WITH FORMALIN **TREATED AUTOLOGOUS TUMOR-CELLS** (TC)

L4 ANSWER 19 OF 44 BIOSIS COPYRIGHT 1999 BIOSIS DUPLICATE 13  
ACCESSION NUMBER: 1983:285245 BIOSIS  
DOCUMENT NUMBER: BA76:42737  
TITLE: INDUCTION OF DELAYED HYPER SENSITIVITY REACTIONS IN CANCER PATIENTS BY CHOLESTEROL HEMI SUCCINATE **TREATED AUTOLOGOUS TUMOR** CELLS.

AUTHOR(S): SKORNICK Y; DRESDALE A R; SINDELAR W F  
CORPORATE SOURCE: BUILDING 10, ROOM 10N206, NATIONAL INST. HEALTH, BETHESDA, MD. 20205.  
SOURCE: J NATL CANCER INST, (1983) 70 (3), 465-468.  
CODEN: JNCIAM. ISSN: 0027-8874.  
FILE SEGMENT: BA; OLD  
LANGUAGE: English

TI INDUCTION OF DELAYED HYPER SENSITIVITY REACTIONS IN CANCER PATIENTS BY CHOLESTEROL HEMI SUCCINATE **TREATED AUTOLOGOUS TUMOR** CELLS.

AB. . . malignant tumors. Patients were given intradermal injections of 106 autologous, irradiated, CHS-treated tumor cells. Control injections consisted of untreated irradiated **tumor** cells, CHS-**treated autologous** normal peripheral lymphocytes, strongly positive skin reactions were observed when CHS-treated tumor cells were used. Untreated irradiated cells gave negative.



L4 ANSWER 20 OF 44 PLUS COPYRIGHT 1999 ACS  
ACCESSION NUMBER: 1983:606601 CAPLUS  
DOCUMENT NUMBER: 99:206601  
TITLE: Vaginal administration of a potent luteinizing hormone-releasing hormone analog (leuprolide)  
AUTHOR(S): Okada, Hiroaki  
CORPORATE SOURCE: Cent. Res. Div., Takeda Chem. Ind., Ltd., Osaka, 532, Japan  
SOURCE: Takeda Kenkyushoho (1983), 42(1/2), 150-208  
CODEN: TAKHAA; ISSN: 0371-5167  
DOCUMENT TYPE: Journal  
LANGUAGE: Japanese  
AB A rational dosage method for leuprolide (I) [53714-56-0] **self-administration** in mammary **tumor** therapy was studied in rats by detg. the ovulation-inducing activity and RIA of serum levels of I and gonadotropin after. . .

✓ L4 ANSWER 21 OF 44 BIOSIS COPYRIGHT 1999 BIOSIS DUPLICATE 14  
ACCESSION NUMBER: 1982:173435 BIOSIS  
DOCUMENT NUMBER: BA73:33419  
TITLE: SEQUENTIAL COMBINATION CHEMO IMMUNO THERAPY FOR VARIOUS MALIGNANT TUMORS CLINICAL AND LABORATORY RESULTS.  
AUTHOR(S): AKIYOSHI T; KAWAGUCHI M; MIYAZAKI S; KOB A F; TSUJI H  
CORPORATE SOURCE: DEP. SURG., RES. INST. BALNEOTHER., KYUSHU UNIV., BEPPU 874, JPN.  
SOURCE: JPN J SURG, (1981) 11 (4), 283-290.  
CODEN: JJSGAY. ISSN: 0047-1909.  
FILE SEGMENT: BA; OLD  
LANGUAGE: English  
AB. . . advanced malignant tumors. The treatment regimen consisted of cyclophosphamide (CY) 200 mg i.v. on day 1, Vibrio cholerae neuraminidase (VCN) **treated autologous tumor** cells admixed with BCG 5-10 mg intradermally on day 4 and mitomycin C (MMC) 10-16 mg and 5-fluorouracil (FU) 500. . .

L4 ANSWER 22 OF 44 CANCERLIT  
ACCESSION NUMBER: 81621250 CANCERLIT  
DOCUMENT NUMBER: 81621250  
TITLE: SEQUENTIAL COMBINATION CHEMOIMMUNOTHERAPY FOR MALIGNANT DISEASE. II. CLINICAL AND LABORATORY RESULTS.  
AUTHOR: Akiyoshi T; Kawaguchi M; Miyazaki S; Koba F; Tsuji H  
CORPORATE SOURCE: Dept. Surgery, Res. Inst. Balneotherapeutics, Kyushu Univ., Beppu-shi, Oita Pref. 874, Japan.  
SOURCE: Gan To Kagaku Ryoho, (1980). Vol. 7, No. 11, pp. 2019-2026.  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
FILE SEGMENT: ICDB; L  
LANGUAGE: Japanese  
ENTRY MONTH: 198108

AB . . . patients with various advanced malignant tumors. The treatment program consisted of cyclophosphamide 200 mg iv on day 1, Vibrio cholerae neuraminidase **treated autologous tumor** cells admixed with BCG 5 to 10 mg id on day 4 and mitomycin C 10 to 16 mg and.

L4 ANSWER 23 OF 44 BIOSIS COPYRIGHT 1999 BIOSIS DUPLICATE 15  
ACCESSION NUMBER: 1980:204575 BIOSIS  
DOCUMENT NUMBER: BA69:79571  
TITLE: TRANSITIONAL CELL CARCINOMA OF THE BLADDER DIFFERENCES BETWEEN PRIMARY TUMOR AND FOLLOWING RELAPSES.  
AUTHOR(S): PIZZA G; VIZA D; FINI M; CUZZOCREA D; MENNITI D; CORRADO F  
CORPORATE SOURCE: DIV. UROL., OSP. M. MALPIGHI, VIA P. PALAGI 9, BOLOGNA, ITALY.

SOURCE: EMBASE, (1980) 6 (1), 45-47.  
CODEN: EUURAV. ISSN: 0302-2838.  
FILE SEGMENT: BA; OLD  
LANGUAGE: English  
AB The presence of tumor-associated antigens in bladder carcinomas was shown in leukocyte migration inhibition and lymphocyte stimulation using formalin-**treated autologous tumor** cells as antigen. The treatment of patients with an in vitro-produced specific transfer factor enhances their reactivity in these tests.. . .

L4 ANSWER 24 OF 44 BIOSIS COPYRIGHT 1999 BIOSIS DUPLICATE 16  
ACCESSION NUMBER: 1980:163653 BIOSIS  
DOCUMENT NUMBER: BA69:38649  
TITLE: TUMOR METASTASES AND CELL MEDIATED IMMUNITY IN A MODEL SYSTEM IN DBA-2 MICE 6. SIMILAR SPECIFICITY PATTERNS OF PROTECTIVE ANTI TUMOR IMMUNITY IN-VIVO AND CYTOLYTIC

THYMUS

DERIVED CELLS IN-VITRO.  
AUTHOR(S): BOSSLET K; SCHIRRMACHER V; SHANTZ G  
CORPORATE SOURCE: INST. IMMUNOL. GENET., DTSCH. KREBSFORSCHUNGSZENT., HEIDELBERG, W. GER.  
SOURCE: INT J CANCER, (1979) 24 (3), 303-313.  
CODEN: IJCNAA. ISSN: 0020-7136.  
FILE SEGMENT: BA; OLD  
LANGUAGE: English  
AB. . . lymphocytes (CTL) were obtained after sensitization in vivo with viable tumor cells and restimulation in vitro for 4-5 days with mitomycin-C-**treated autologous tumor** cells.  
Anti-Eb and anti-ESb CTL showed high cytolytic activity in a 4-h 51Cr release assay against the autologous tumor lines.. . .

L4 ANSWER 25 OF 44 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V. DUPLICATE 17  
ACCESSION NUMBER: 79249432 EMBASE  
DOCUMENT NUMBER: 1979249432  
TITLE: Immunotherapy of spontaneous mammary tumors in mongrel dogs

with autologous tumor cells and neuraminidase.  
AUTHOR: Sedlacek H.H.; Weise M.; Lemmer A.; Seiler F.R.  
CORPORATE SOURCE: Res. Lab. Behringwerke AG, 3550 Marburg/Lahn, Germany  
SOURCE: Cancer Immunology Immunotherapy, (1979) 6/1 (47-58).  
CODEN: CIIMDN

COUNTRY: Germany  
DOCUMENT TYPE: Journal  
FILE SEGMENT: 037 Drug Literature Index  
016 Cancer  
026 Immunology, Serology and Transplantation  
LANGUAGE: English

AB . . . blindly distributed into six groups in three consecutive studies.

The results show that the therapeutic effect of the injection of VCN-**treated autologous tumor** cells depends on the number of tumor cells injected: injection of  $2 \times 10^7$  tumor cells repeatedly induced regression of the residual. . . .

L4 ANSWER 26 OF 44 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.  
ACCESSION NUMBER: 79042556 EMBASE  
DOCUMENT NUMBER: 1979042556  
TITLE: Spontaneous mammary tumors in mongrel dogs. A relevant model to demonstrate tumor therapeutical success by application of neuraminidase-treated tumor cells.  
AUTHOR: Sedlacek H.H.; Seiler F.R.  
CORPORATE SOURCE: Behringwerke AG, D-3550 Marburg/Lahn, Germany  
SOURCE: Developments in Biological Standardization, (1978) VOL. 38/- (399-412).  
CODEN: DVBSA3  
COUNTRY: Switzerland

DOCUMENT TYPE: Journal  
FILE SEGMENT: 037 Drug Literature Index  
026 Immunology, Serology and Transplantation  
016 Cancer  
010 Obstetrics and Gynecology  
004 Microbiology

LANGUAGE: English

AB . . . certain time intervals. The results after a follow-up examination

period of about three years show that the tumor-therapeutical effect of VCN-**treated autologous tumor** cells depends on the number of tumor cells injected:  $2 \times 10^7$  tumor cells induce long lasting tumor regression, prolongation. . .

L4 ANSWER 27 OF 44 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.

ACCESSION NUMBER: 79042555 EMBASE

DOCUMENT NUMBER: 1979042555

TITLE: Possible immunological action of Vibrio cholerae neuraminidase (VCN) in tumor immunotherapy.

AUTHOR: Sedlacek H.H.; Johannsen R.; Seiler F.R.

CORPORATE SOURCE: Behringwerke AG, D-3550 Marburg/Lahn, Germany

SOURCE: Developments in Biological Standardization, (1978) VOL. 38/- (387-398).

CODEN: DVBSA3

COUNTRY: Switzerland

DOCUMENT TYPE: Journal

FILE SEGMENT: 037 Drug Literature Index  
016 Cancer  
026 Immunology, Serology and Transplantation  
004 Microbiology

LANGUAGE: English

AB From literature it is known that the injection of VCN-**treated autologous tumor** cells into **tumor-bearing** mice immunologically induced tumor regression. The increase of immunogenicity of such treated cells has been said to be contributed to. . .

L4 ANSWER/28 OF 44 BIOSIS COPYRIGHT 1999 BIOSIS DUPLICATE 18

ACCESSION NUMBER: 1979:162604 BIOSIS

DOCUMENT NUMBER: BA67:42604

TITLE: DEMONSTRATION OF SPECIFIC CELL MEDIATED ANTI TUMOR IMMUNITY

IN LUNG CANCER TO AUTOLOGOUS TISSUE EXTRACTS.

AUTHOR(S): DEAN J H; JERRELLS T R; CANNON G B; KIBRITE A; BAUMGARDNER B; WEESE J L; SILVA J; HERBERMAN R B

CORPORATE SOURCE: BIOMED. RES. DIV., DEP. IMMUNOL., LITTON BIONETICS INC. 5516 NICHOLSON LANE, KENSINGTON, MD. 20795, USA.

SOURCE: INT J CANCER, (1978) 22 (4), 367-377.

CODEN: IJCNAW. ISSN: 0020-7136.

FILE SEGMENT: BA; OLD

LANGUAGE: English

AB. . . interactions as measured in a microculture (200 .mu.l) lymphocyte proliferation (LP) assay. Positive lymphoproliferative responses were observed with cryopreserved intact mitomycin-C-**treated autologous tumor** cells (8/12 or 67% patients reactive) and with hypotonic membrane extracts (HMP) of tumor cells (28/40 or 70%). Good correlation. . .

L4 ANSWER 29 OF 44 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.DUPLICATE 19

ACCESSION NUMBER: 79142220 EMBASE

DOCUMENT NUMBER: 1979142220

TITLE: Specificity of cell membrane antigens in prostate cancer.

AUTHOR: Brannen G.E.; Coffey D.S.

CORPORATE SOURCE: Madigan Army Med. Cent., Tacoma, Wash. 98431, United States

SOURCE: National Cancer Institute Monograph, (1978) Monogr. 49/- (251-253).

COUNTRY: United States  
DOCUMENT TYPE: Journal  
FILE SEGMENT: 016 Cancer  
026 Immunology, Serology and Transplantation  
020 Gerontology and Geriatrics  
028 Urology and Nephrology  
LANGUAGE: English  
AB . . . given intradermal injections of soluble tumor antigens extracted from their tumors; exhibited a cutaneous, delayed type hypersensitivity response to the **injected autologous tumor** extracts. No positive reactions were observed in response to solubilized components of control tissues, including BPH. These observations suggest that. . .

L4 ANSWER 30 OF 44 CANCERLIT  
ACCESSION NUMBER: 78804857 CANCERLIT  
DOCUMENT NUMBER: 78804857  
TITLE: ACTIVE SPECIFIC IMMUNOTHERAPY OF ADVANCED RENAL-CELL CARCINOMA.  
AUTHOR: Tykka H; Oravisto K J; Lehtonen T; Sarna S; Tallberg T  
CORPORATE SOURCE: Lab. Immunology, Helsinki Univ. Central Hosp.,  
Haartmaninkatu 3, 00290 Helsinki 29, Finland.  
SOURCE: Eur Urol, (1978). Vol. 4, No. 4, pp. 250-258.  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
FILE SEGMENT: CATH; L  
LANGUAGE: English  
ENTRY MONTH: 197811  
AB . . . old) with advanced adenocarcinoma of the kidney (Stage III-IV, Grade I-III). None had brain metastases. Postoperative immunotherapy (ImT) with ethyl chloroformate-**treated autologous tumor** vaccine and an individually selected antigen (Candida albicans or tuberculin-purified protein derivative) was given id (av, 1x/mo until the material. . .

L4 ANSWER 31 OF 44 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.  
ACCESSION NUMBER: 78158636 EMBASE  
DOCUMENT NUMBER: 1978158636  
TITLE: Effect of vibrio cholerae neuraminidase (VCN) **treated autologous tumor** cells on the growth of the spontaneous mammary tumor in dogs.  
AUTHOR: Sedlacek H.H.; Weise M.; Meesmann H.; Seiler F.R.  
CORPORATE SOURCE: Behringw. AG, Marburg/Lahn, Germany  
SOURCE: Allergologia et Immunopathologia, (1977) 5/4 (383-384).  
CODEN: AGIMBJ  
COUNTRY: Spain  
DOCUMENT TYPE: Journal  
FILE SEGMENT: 037 Drug Literature Index  
LANGUAGE: English  
TI Effect of vibrio cholerae neuraminidase (VCN) **treated autologous tumor** cells on the growth of the spontaneous mammary tumor in dogs.

L4 ANSWER 32 OF 44 CANCERLIT  
ACCESSION NUMBER: 77807757 CANCERLIT  
DOCUMENT NUMBER: 77807757  
TITLE: NEURAMINIDASE AND TUMOR IMMUNOTHERAPY.  
AUTHOR: Sedlacek H H; Seiler F R; Schwick H G  
CORPORATE SOURCE: Bahringerwerke AG, D-3550 Marburg/Lahn, W. Germany.  
SOURCE: Klin Wochenschr, (1977). Vol. 55, No. 5, pp. 199-214.  
ISSN: 0023-2173.  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
FILE SEGMENT: CATH; L  
LANGUAGE: English  
ENTRY MONTH: 197709

AB . . . immunotherapy are presented. Among recurrent and metastatic melanoma patients who survived long enough to receive sc injections of irradiated V cholerae-**treated autologous tumor** cells and BCG during the last phase of a 4-phase immunotherapy program, 6 showed complete regression over periods of 6-30. . .

L4 ANSWER 33 OF 44 CANCERLIT

ACCESSION NUMBER: 77806132 CANCERLIT  
DOCUMENT NUMBER: 77806132  
TITLE: ABNORMALITIES OF MONOCYTE CHEMOTAXIS IN PATIENTS WITH MELANOMA: EFFECTS OF IMMUNOTHERAPY AND TUMOR REMOVAL.  
AUTHOR: Snyderman R; Seigler H F; Meadows L  
CORPORATE SOURCE: Box 3892, Duke Univ. Medical Center, Durham, NC 27710.  
SOURCE: J Natl Cancer Inst, (1977). Vol. 58, No. 1, pp. 37-44.  
ISSN: 0027-8874.  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
FILE SEGMENT: CATH; L  
LANGUAGE: English  
ENTRY MONTH: 197707

AB . . . cells, then readministering these cells iv (Phase III). Patients were challenged 30 days later with an sc inoculum of irradiated neuraminidase-**treated autologous tumor** cells plus BCG (Phase IV). After immunotherapy or surgical removal of the neoplasm, the number of MCR-depressed patients dropped from. . .

L4 ANSWER 34 OF 44 CANCERLIT

ACCESSION NUMBER: 76800139 CANCERLIT  
DOCUMENT NUMBER: 76800139  
TITLE: CYTOTOXICITY REACTIONS DURING IMMUNOTHERAPY OF MELANOMA WITH NEURAMINIDASE ALTERED AUTOLOGOUS TUMOR CELLS.  
AUTHOR: Miller E E; Rosato F E; Brown A S; Moskovitz A; Johnson J  
CORPORATE SOURCE: Harrison Dept. Surgical Res., Univ. Pennsylvania Sch. Medicine, Philadelphia, PA.  
SOURCE: J Surg Oncol, (1976). Vol. 8, No. 1, pp. 31-34.  
ISSN: 0022-4790.  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
FILE SEGMENT: CATH; L  
LANGUAGE: English  
ENTRY MONTH: 197611

AB . . . patterns of changing serum cytotoxicity and serum blocking effect suggested the phenomena may be related, and that active immunotherapy with neuraminidase-**treated autologous tumor** cells may play a role in the unblocking of serum blocking effect and prevention of metastases. (12 refs)

L4 ANSWER 35 OF 44 CANCERLIT

ACCESSION NUMBER: 77607436 CANCERLIT  
DOCUMENT NUMBER: 77607436  
TITLE: REGRESSION OF SPONTANEOUS MAMMARY TUMORS IN DOGS AFTER INJECTION OF VIBRIO CHOLERAEE NEURAMINIDASE (VCN)-TREATED TUMOR CELLS.  
AUTHOR: Sedlacek H H; Meesmann H; Seiler F R  
CORPORATE SOURCE: Berring Institute, 355 Marburg(Lahn), FRG.  
SOURCE: Proc Am Assoc Cancer Res, (1975). Vol. 16, pp. 141.  
ISSN: 0569-2261.  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
FILE SEGMENT: ICDB; L  
LANGUAGE: English  
ENTRY MONTH: 197704

AB . . . min/37 degrees C). Group 1 received twice  $1 \times 10^{*7}$ ; Group 2 was injected twice with  $5 \times 10^{*7}$  likewise **treated autologous tumor** cells sc in the neck on the day of operation and on the next day. The control group was equally. . .

ACCESSION NUMBER: 76002176 EMBASE  
DOCUMENT NUMBER: 1976002176  
TITLE: Specificity of cell membrane antigens in prostatic cancer.  
AUTHOR: Brannen G.E.; Gomolka D.M.; Coffey D.S.  
CORPORATE SOURCE: James Buchanan Brady Urol. Inst., Johns Hopkins Hosp., Baltimore, Md., United States  
SOURCE: CANCER CHEMOTHER.REP., (1975) 59/1 (127-138).  
CODEN: CNCRA6  
DOCUMENT TYPE: Journal  
FILE SEGMENT: 037 Drug Literature Index  
016 Cancer  
026 Immunology, Serology and Transplantation  
028 Urology and Nephrology  
LANGUAGE: English

AB . . . antigens extracted from their own tumors. Three of the seven patients exhibited a cutaneous delayed type hypersensitivity response to the **injected autologous tumor** extracts. No positive reactions were observed in response to solubilized components of control tissues, including benign prostatic hyperplasia. The significance.

L4 ANSWER 37 OF 44 TOXLINE

ACCESSION NUMBER: 1995:63643 TOXLINE  
DOCUMENT NUMBER: IPA-75-146077  
TITLE: Positive antiglobulin test after BCG immunotherapy.  
COMMENT: Letters  
AUTHOR: Collier B S; Lundberg W B; Albright L; Ommaya A K; Gralnick H R  
CORPORATE SOURCE: National Institutes of Health, Bethesda, Maryland 20014.  
SOURCE: N. Engl. J. Med, (1974). Vol. 291, Aug 29, pp. 474 (REF).  
CODEN: NEJMAG. ISSN: 0028-4793.  
FILE SEGMENT: IPA  
LANGUAGE: English  
OTHER SOURCE: IPA 12-146077  
ENTRY MONTH: 199507

AB . . . direct (and later indirect) antiglobulin test developed after 8 months of the following antitumor therapy: biweekly S.C. injections of neuraminidase **treated autologous tumor** cells; monthly intradermal BCG and intratumoral purified protein derivative of tuberculin (via a reservoir); systemic lomustine (CCNU); and intratumoral 8-azaguanine.

L4 ANSWER 38 OF 44 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.

ACCESSION NUMBER: 76112239 EMBASE  
DOCUMENT NUMBER: 1976112239  
TITLE: Regression of spontaneous mammary tumors of dogs after injection of neuraminidase treated tumor cells: a preliminary communication.  
AUTHOR: Sedlacek H.H.; Meesmann H.; Seiler F.R.  
CORPORATE SOURCE: Behring Inst., Marburg, Germany  
SOURCE: BEHRING INST.MITT., (1974) No.55/- (349-355).  
CODEN: XXXXXB  
DOCUMENT TYPE: Journal  
FILE SEGMENT: 037 Drug Literature Index  
005 General Pathology and Pathological Anatomy  
026 Immunology, Serology and Transplantation  
016 Cancer  
LANGUAGE: English

AB . . . and subsequently with highly purified VCN (100 U/ml/5 x 10<sup>7</sup> cells/30 min/37.degree. C). Twelve dogs received 1 x 10<sup>7</sup> likewise **treated autologous tumor** cells s.c. in the neck on the day of operation and on the day thereafter. Clinical

L4 ANSWER 39 OF 44 BIOSIS COPYRIGHT 1999 BIOSIS  
 ACCESSION NUMBER: 1974:73363 BIOSIS  
 DOCUMENT NUMBER: BR10:73363  
 TITLE: VIBRIO-CHOLERA NEURAMINIDASE **TREATED**  
**AUTOLOGOUS TUMOR** CELLS AS IMMUNO THERAPY  
 IN HUMAN TUMORS.  
 AUTHOR(S): ROSATO F E; MILLER E; ROSATO E F; MULLIS W; JOHNSON J;  
 BROWN A  
 SOURCE: Proc. Am. Assoc. Cancer Res., (1974) 15, 159.  
 CODEN: PAACA3. ISSN: 0569-2296.  
 DOCUMENT TYPE: Conference  
 FILE SEGMENT: BR; OLD  
 LANGUAGE: Unavailable  
 TI VIBRIO-CHOLERA NEURAMINIDASE **TREATED AUTOLOGOUS**  
**TUMOR** CELLS AS IMMUNO THERAPY IN HUMAN TUMORS.

L4 ANSWER 40 OF 44 SCISEARCH COPYRIGHT 1999 ISI (R)  
 ACCESSION NUMBER: 74:116289 SCISEARCH  
 THE GENUINE ARTICLE: S2695  
 TITLE: VIBRIO CHOLERA NEURAMINIDASE (VCN) **TREATED**  
**AUTOLOGOUS TUMOR-CELLS** AS IMMUNOTHERAPY  
 IN HUMAN TUMORS  
 AUTHOR: ROSATO F E (Reprint); MILLER E; ROSATO E F; MULLIS W;  
 JOHNSON J; BROWN A  
 CORPORATE SOURCE: UNIV PENN, DEPT SURG, 3400 SPRUCE ST, PHILADELPHIA, PA,  
 19104  
 COUNTRY OF AUTHOR: USA  
 SOURCE: PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER  
 RESEARCH, (1974) Vol. 15, No. MAR, pp. 159.  
 DOCUMENT TYPE: Conference; Journal  
 LANGUAGE: ENGLISH  
 REFERENCE COUNT: No References  
 TI VIBRIO CHOLERA NEURAMINIDASE (VCN) **TREATED AUTOLOGOUS**  
**TUMOR-CELLS** AS IMMUNOTHERAPY IN HUMAN TUMORS

L4 ANSWER 41 OF 44 CANCERLIT  
 ACCESSION NUMBER: 74706277 CANCERLIT  
 DOCUMENT NUMBER: 74706277  
 TITLE: IMMUNOLOGICAL STUDIES IN ACUTE LEUKEMIA.  
 AUTHOR: Santos G W; Mullins G M; Bias W B; Anderson P N; Graziano  
 K  
 D; Klein D L; Burke P J  
 CORPORATE SOURCE: Dept. Med., Johns Hopkins Univ., Baltimore, Md.  
 SOURCE: Recent Results Cancer Res, (1974). Vol. 47, pp. 17-24.  
 ISSN: 0080-0015.  
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
 FILE SEGMENT: CARC; L  
 LANGUAGE: English  
 ENTRY MONTH: 197512

AB . . . unresponsive to the antigens tested in the skin tests but in no  
 instance was a delayed hypersensitivity response to intradermally  
**injected autologous tumor** cells found. Nine  
 normal siblings were found to be HL-A identical to their leukemic  
 siblings  
 and eight of these responded.

L4 ANSWER 42 OF 44 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.DUPLICATE 21  
 ACCESSION NUMBER: 75062773 EMBASE  
 DOCUMENT NUMBER: 1975062773  
 TITLE: Vibrio cholera neuraminidase (VCN) **treated**  
**autologous tumor** cells as immunotherapy  
 in human tumors.  
 AUTHOR: Rosato F.E.; Miller E.; Mullis W.; et al.  
 CORPORATE SOURCE: Dept. Surg., Univ. Pennsylvania, Philadelphia, Pa. 19104,

United States  
SOURCE: European Surgical Research, (1974) sup 1 (13).  
CODEN: EUSRBM  
DOCUMENT TYPE: Journal  
FILE SEGMENT: 037 Drug Literature Index  
LANGUAGE: English  
TI Vibrio cholera neuraminidase (VCN) **treated autologous**  
**tumor** cells as immunotherapy in human tumors.

L4 ANSWER 43 OF 44 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.

ACCESSION NUMBER: 75100801 EMBASE

DOCUMENT NUMBER: 1975100801

TITLE: Vibrio cholera neuraminidase (VCN) **treated**  
**autologous tumor** cells as immunotherapy  
in human tumors.

AUTHOR: Rosato F.E.; Miller E.; Rosato E.F.; et al.

CORPORATE SOURCE: Dept. Surg., Univ. Pennsylvania, Philadelphia, Pa. 19104,  
United States

SOURCE: Proceedings of the American Association for Cancer  
Research, (1974) Vol. 15 No. 703/-.  
CODEN: PAACA3

DOCUMENT TYPE: Journal

LANGUAGE: English

TI Vibrio cholera neuraminidase (VCN) **treated autologous**  
**tumor** cells as immunotherapy in human tumors.

L4 ANSWER 44 OF 44 CANCERLIT

ACCESSION NUMBER: 71700940 CANCERLIT

DOCUMENT NUMBER: 71700940

TITLE: EFFECT OF INOCULA OF BENZO[A]PYRENE-TREATED SARCOMA CELLS  
ON GROWTH OF PRIMARY TUMORS IN RATS.

AUTHOR: Hall J G; Glover D J

CORPORATE SOURCE: Chester Beatty Res. Inst., Sutton, Surrey, England.

SOURCE: J Natl Cancer Inst, (1970). Vol. 45, No. 6, pp.  
1163-1168.

ISSN: 0027-8874.

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

FILE SEGMENT: CARC; L

LANGUAGE: English

ENTRY MONTH: 197512

AB . . . not act by increasing the strength of the tumor-specific  
antigen,

for inocula of carcinogen-allogenic treated tumor cells and inocula of  
carcinogen-**treated autologous tumor** cells  
had almost the same efficacy in tumor growth retardation.



FILE 'BIOSIS, EMBASE, MEDLINE, CAPLUS, APIPAT, CROPU, DGENE, DPCI,  
EUROPATFULL, IFIPAT, INPADOC, JAPIO, PAPERCHEM2, PATDD, PATDPA, PATOSDE,  
PATOSEP, PATOSWO, PIRA, RAPRA, TULSA, TULSA2, USPATFULL, LIFESCI,  
TOXLINE, CANCERLIT, SCISEARCH' ENTERED AT 13:37:20 ON 19 AUG 1999

L1 39791 S (ADMINIST? OR INJECT? OR TREAT?) (A) (PATEINT? OR OWN OR SELF  
O  
L2 3022524 S TUMOR? OR TUMOUR?  
L3 103 S L1(3A)L2  
L4 44 DUP REM L3 (59 DUPLICATES REMOVED)